Torjman Marc C, Machnicki Robert, Lessin Jennifer, Loeum Channy, Steinberger Douglas, Mycroft Sarah, Joseph Jeffrey I
a Department of Anesthesiology , Sidney Kimmel Medical College at Thomas Jefferson University , Philadelphia , PA , USA.
b Unilife Corporation , York , PA 17406 , USA.
Expert Opin Drug Deliv. 2017 Jan;14(1):7-13. doi: 10.1080/17425247.2017.1252748. Epub 2016 Nov 4.
Introduction of a wearable device for subcutaneous delivery of larger volume bolus injections would encourage patient compliance and reduce the burden on healthcare services. With one such wearable device commercially available, this study examined the safety and functionality of an investigational device in volunteers.
Four devices were applied to the subject's abdomen: 1) Investigational Device, 2) Investigational Device: subject movement, 3) Control Device: FDA-cleared syringe driver with FDA-cleared infusion set, 4) Control Device: FDA-cleared syringe driver attached to investigational device. Three milliliters of saline were infused through the four devices over 3 minutes.
84 devices were applied to 21 subjects. Three milliliters of saline were safely delivered subcutaneously from the investigational and control devices. Two control devices had occlusions and in each case the pump reached its high pressure limit of 12 psi. VAS pain measurements showed minimal pain for all subjects. Pain scores were significantly (p < 0.001) higher than baseline at the end of injection: mean pain level ranged from 2.0-22.0 mm.
The investigational device performed as intended with minimal pain during needle insertion and infusion, and no leaking of fluid at the skin puncture site. Two occlusions occurred with the control devices.
引入一种用于皮下大容量推注给药的可穿戴设备将提高患者的依从性,并减轻医疗服务负担。鉴于已有一款此类可穿戴设备上市,本研究对一款试验性设备在志愿者中的安全性和功能进行了检验。
在受试者腹部应用4种设备:1)试验性设备;2)试验性设备:受试者活动状态;3)对照设备:经美国食品药品监督管理局(FDA)批准的注射器驱动装置及经FDA批准的输液装置;4)对照设备:连接试验性设备的经FDA批准的注射器驱动装置。在3分钟内通过这4种设备输注3毫升生理盐水。
对21名受试者应用了84台设备。试验性设备和对照设备均安全地将3毫升生理盐水皮下输注。两台对照设备出现堵塞,在每种情况下泵均达到其12磅力/平方英寸的高压极限。视觉模拟评分法(VAS)疼痛测量显示所有受试者疼痛轻微。注射结束时疼痛评分显著高于基线(p < 0.001):平均疼痛程度为2.0 - 22.0毫米。
试验性设备按预期运行,在针头插入和输注过程中疼痛极小,且皮肤穿刺部位无液体渗漏。对照设备出现两例堵塞。